Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
Ren, L., Grina, J., Moreno, D., Blake, J.F., Gaudino, J.J., Garrey, R., Metcalf, A.T., Burkard, M., Martinson, M., Rasor, K., Chen, H., Dean, B., Gould, S.E., Pacheco, P., Shahidi-Latham, S., Yin, J., West, K., Wang, W., Moffat, J.G., Schwarz, J.B.(2015) J Med Chem 58: 1976-1991
- PubMed: 25603482 
- DOI: https://doi.org/10.1021/jm501921k
- Primary Citation of Related Structures:  
4XJ0 - PubMed Abstract: 
Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.
Organizational Affiliation: 
Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301, United States.